Skip to main content

Advertisement

Table 1 Demographic and clinical characteristics

From: Rituximab suppresses disease activity after natalizumab withdrawal: an exploratory study

Gender Age at natalizumab start Relapses in the year before natalizumab N° of natalizumab infusions EDSS after last natalizumab infusion Brain MRI at 6 months after rituximab Brain MRI at 12 months after rituximab
F 29 2 35 1.5 unchanged unchanged
F 44 2 76 3.5 unchanged unchanged
F 32 1 27 2.0 unchanged unchanged
F 38 2 69 2.0 unchanged unchanged
M 25 1 37 4.5 unchanged unchanged
F 33 2 39 3.5 unchanged unchanged
F 40 1 22 2.0 unchanged unchanged
F 30 2 67 3.5 unchanged n.a.
F 35 2 71 2.0 unchanged n.a.
M 32 2 30 7.0 unchanged unchanged
  1. n.a. not available (follow up <1 year)